Pradžia › Neuroblastoma › Koloradas
Neuroblastoma klinikiniai tyrimai Koloradas
8 tyrimai dėl Neuroblastoma ieško dalyvių vietose Koloradas.
Miestai Koloradas
Oficialus tyrimo tekstas (anglų kalba)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Children's Hospital Colorado, Aurora
Renkami dalyviai3 fazė
Iki 30 metų · Visoms lytims · Atnaujinta 2026-10-02 · NCT06172296Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016), Aurora
Renkami dalyviai1/2 fazė
6 Months – 25 Years · Visoms lytims · Atnaujinta 2026-09-17 · NCT06395103Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Children's Hospital Colorado, Aurora
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
Renkami dalyviai3 fazė
365 Days – 30 Years · Visoms lytims · Atnaujinta 2026-08-25 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital Colorado, Aurora
Renkami dalyviai1/2 fazė
12 Months – 30 Years · Visoms lytims · Atnaujinta 2026-08-25 · NCT04851119NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- Children's Hospital Colorado, Aurora
Renkami dalyviai2 fazė
Amžius nuo 1 iki 31 · Visoms lytims · Atnaujinta 2026-07-20 · NCT06450041Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
- Children's Hospital Colorado, Aurora
Renkami dalyviai1/2 fazė
12 Months – 30 Years · Visoms lytims · Atnaujinta 2026-05-19 · NCT04901702Neuroblastoma Biology Study
- Children Hospital of Colorado, Aurora
Renkami dalyviaiStebimasis tyrimas
31 Days – 99 Years · Visoms lytims · Atnaujinta 2026-03-23 · NCT01587300A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
- Children's Hospital of Colorado, Aurora
Renkami dalyviai2 fazė
18 Months – 40 Years · Visoms lytims · Atnaujinta 2025-08-12 · NCT05135975Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.